Original Article

Role Of Herbal Nanotechnoloigy In Triple Negative Breast Cancer

Vasanth S[1], Angara Ananya Shree[1], Jalak Bhat[1], Bala Gurivi Reddy Vemireddy[2], Vinod Kumar Reddy Bondu[3], Navanita Sivarama kumar[1], Shanker Kalakotla[1], Sudharshan Reddy Dachani*[4]

[1]Department of Pharmacognosy & Phyto-Pharmacy, JSS College of Pharmacy, JSS Academy of Higher Education & Research, Ooty, Nilgiris, Tamil Nadu, India.
[2] PGT Physics, New Middle East International School, Riyadh, Kingdom of Saudi Arabia
[3]Department of Pharmaceutical Biotechnology, JSS College of Pharmacy, JSS Academy of Higher Education & Research, Ooty, Nilgiris, Tamil Nadu, India.

*Corresponding Author: Sudharshan Reddy Dachani, PhD

*[4]Department of Pharmacy Practice & Pharmacology, College of Pharmacy, Shaqra University, Al-Dawadmi Campus, Al-Dawadmi-11961, Kingdom of Saudi Arabia (KSA) , Mail ID: suhasinraydaa@su.edu.sa
DOI: 10.47750/pnr.2023.14.S02.343

Abstract

Triple-negative breast cancer is a type of cancer that has absence in certain receptor systems like Human epidermal growth factor receptor-2 (HER2), progesterone receptor (PR), and oestrogen receptor (ER) (1). It is tough to treat, and there aren't many therapies that work right now. Through the use of nanoparticles, researchers have developed new approaches to treat patients with TNBC. These new drugs are designed to target the different genetic mutations that are known to affect the development of this disease. The use of NDDSs with nano herbal technology has numerous advantages, such as their ability to improve the therapeutic outcome, and systemic action and reduced systemic toxicity.

Keywords: NDDS, TNBC, Nanotechnology, Herbal medicine, metastasize, Nanoparticle, Chemotherapy

INTRODUCTION

Cancer is the uncontrolled, rapid proliferation of aberrant cells and it is the 2nd most common disease in women after lung cancer (2).According to estimates, there will be 287,850 cases of invasive breast cancer and 51,400 cases of non-invasive breast cancer were reported in the United States in 2022(3). Invasive cancer that spreads to distant sites and non-invasive cancer that is found in lobules (1/3rd) and ducts (2/3rd), respectively, cause high cases in British Columbia (3).Progesterone receptor , human epidermal growth factor receptor 2 , and oestrogen receptor protein expression are negatively expressed in TNBC. As it displays factors including accelerated lymph node advancement, elevated mitosis, proliferation indicators, numerous apoptosis, and high nuclear-cytoplasmic ratio (4). Epithelial-mesenchymal transition, which controls cancer cell motility, contributes to the major invasion of TNBC. Ficus species bark, roots, leaves, and latex were once utilized in cancer treatment (5).Tri-negativity affects 15% of breast cancer cases (TNBC), which has a low survival time and is resistant to hormone therapy (6). Compared to NHW women, NHB women have double the age-adjusted rates of TNBC(10). Some remedies are customary chemotherapy, radiotherapy, Surgical procedure and targeted and immune therapy. For a favorable response, targeted administration with nano therapy by herbals is used most often (7). Finally, the exploration of TNBC's need for the formulation, marker identification, and effective treatment. The uncoordinated pharmacodynamic (PD) and pharmacokinetic (PK) characteristics of the many medications utilized are a burden on the conventional strategy, although it has contributed to some therapeutic improvements. As a result, the existing therapy regimens have demonstrated low in general endurance rates and low quality of life, as well as restricted remedial adequacy, expanded drug obstruction, and expanded harmfulness (7).Additionally, conventional combination therapy cannot diagnose the of absence of wanted viability and the co-presence of all chemotherapeutic medications endorsed for chemotherapy in the important synergistic proportion(8).Importantly, when constructing the therapeutic regimen, The choice between accessible guileless and regulated discharge definitions should be approached in a rationalistic manner.

For the development of such successful medicines meant to elicit a favorable response in TNBC , the clinical gamble to-help proportion should be assessed (9).Additional research efforts suggest that chemotherapy, excellent care, immunotherapy, designated care, and delivery methods on nanocarriers would all be used as techniques to increase the effectiveness of TNBC treatment (10). The objective of the ongoing survey is to decide the clinical need that is neglected in these growths and to assess any potential advantages provided by the tried-and-true nano-formulation techniques. The effectiveness of administering a single medication in addition combining polymer and lipid based nano carrier to simultaneously deliver numerous chemotherapeutic drugs to both neoplasms

Herbal medicine incorporated nanotechnology

Nanotechnology-infused herbal medicine has a significant therapeutic effect with few side effects (11).Nanotechnology of NDDS is applied to cancer therapy to achieve target drug delivery, selectivity, specificity, safety, effectiveness, frequent dose reduction, and decrease the use of conventional drugs. The increased surface area leads to quick dissolution. In BBB, permeation, and retention take place. Low toxicity ensures a sustained therapeutic effect. Enhanced absorption and solubility and decreased elimination are two effects of nanotechnology(12).

Formulation of nanoparticles and its therapeutic action

s.no	Herbal nanoparticle	purpose	Method of synthesis	references
1	Curcumin	powerful tumor-fighting and anticancer properties	milling technique in wet	(13)
2	Berberine	Multiple tumours and inflammation	gelation in ionic stage	(14)
3	Camptothecin	effective anti-cancer	contained in a hydrophobically modified glycol capsule	(15)
4	dodder	carcinogenesis	Nano precipitation	(16)

Effects of nanoparticles on the body enter via several routes such as Translocated lungs, Skin absorption, and intestinal absorption, brain-blood barrier (BBB). Healthcare cost reduction is done by decreased length of patient stays, Enhanced effectiveness of nano therapy, Effective therapy for a serious illness(17). According to the BCC analysis, the global nanomedicine market is supposed to increment at a build yearly development rate (CAGR) of 15.3 % from 2021 to 2026, reaching $493.5 billion.(18)

Nanoparticle in chemotherapy:

Nanoparticles used in immunotherapies combined chemotherapy or radiotherapy with immunostimulatory or immunomodulatory substances. Through co-conveyance of antigen and adjuvant, the presence of a few antigens to enact different dendritic cell targets, and ceaseless arrival of antigens for supported invulnerable initiation, standalone nanoparticle vaccines work as adequate T cell responses to destroy malignancies(19).To change the immunological environment of tumors and enhance response, sub-atomic blockers of resistant suppressive variables can likewise be co-embodied in nanoparticle immunizations. Nano approaches to modulate Host cell response for cancer therapy include artificial antigen presentation cells and immunological depots positioned around cancers for in situ immunization (20).The way in to the use of nanomaterials inside TNBC will be a high articulation of disease targets and ligands by means of nanomaterials joined with different treatments (for example, chemotherapy, light-beam treatment and radiotherapeutics) to accomplish helpful collaborative effects. Ab antibodies against idiotypic types and infections connected with malignant growth, DNA immunizations, and dendritic cell antibodies are examples of cancer vaccines(21)

Biomarkers

Biomarkers utilized essentially for risk appraisal, screening, differential conclusion, treatment reaction expectation, guess assurance, and illness movement observation additionally go through insightful approval, clinical approval, and clinical utility evaluation as a feature of routine clinical consideration.(22).

Uses	Example	Reference
Gauge the gamble of creating disease	mutation in the BRCA1 gene	(23)
Decide the anticipation of the infection	21 quality repeat score for gene recurrence	(24)
Choose the expectation of the disease	HER2 articulation and anti-Her2 treatment	(25)
	ER articulation	(26)
Screen for reaction or movement in metastatic illness	CEA (bosom malignant growth) and CA15-3	(27)

Molecular Biomarker	Mutation of TNBC (%)	Main Function	References
TP53 gene	75-80%	Apoptosis	(28)
EGFR	13–78 %	Cellular growth	(30)
NOTCH pathway	~10%	Cell Proliferation and Differentiation	(34)
c-KIT	50%	Cell transformation and differentiation	(31)
Ki-67	45-53%	Cell proliferation	(29)
VEGF	32 %–62 %	Angiogenesis	(52)
Protein PD-L1	15-30%	Tumour immune evasion process	(57)
Androgen receptor	10-55%	Cell proliferation and dedifferentiation	(32)
BRCA1 and *BRCA2* Genes	14–20 % (Germline mutations)	DNA-double strand break repair	(33)
Phosphatidylinositol-3-kinase pathway	~25%	Cell Proliferation	(35)

Therapy:

Pembrolizumab should be taken before chemotherapy in grown-up patients with locally repetitive, hopeless, or meta statical TNBC. For a maximum of two years, or until the infection worsens or there is serious poisoning, the recommended dosage is 200 mg at regular intervals or 400 mg on demand. When combined with pembrolizumab, gemcitabine (1000 mg/m2) and carboplatin (AUC 2 mg/mL/min) are administered intravenously on Days 1 and 8 at regular intervals of 21

days. paclitaxel 90 mg/m2, Paclitaxel protein-bound 100 mg/m2, or gemcitabine 1000 mg/m2 + carboplatin AUC 2 mg/mL/min are options. (36)

Some nanocarrier active ingredients are liposome contains (doxorubicin, vinorelbine, paclitaxel) , lipid-charged complexes contain paclitaxel, polymeric nanoparticles contain paclitaxel, docetaxel, polymeric—lipidic nanoparticle contains paclitaxel polymeric Micelles contain Cynviloq™ and Abraxane® (38), Polymeric Drug conjugate contains (Paclitaxel poliglumex, Paclitaxel–Angiopep2 conjugate)

a. Nanocarrier alternatives to conventional therapy

Utilizing nanocarrier-based conveyance of the medications, the viable interpretation of the regular blend medicine treatment with expanded PK-PD profiles and worldly , spatial occurrence at the growth site might be achieved (39). Critically, for compelling restorative outcomes after foundational organization, the directed conveyance of the prescriptions during travel to the cancer cells and inside the growth cells should be laid out. When anticancer medications are delivered via nanocarriers, the circulation half-life and bioavailability are almost always improved, which improves the introduction of the drugs at their objective locales of activity. These nanocarriers' Surface change based on PEGylation has allowed for regulated drug delivery to tumor cells with passive targeting options and reduced systemic exposure to healthy tissues. Numerous biodegradable and biocompatible formulations of passively targeted nanoparticulate based on lipids and polymers have undergone preclinical and clinical testing as part of combination therapy. Various nanosized drug conveyance vehicles have subbed innocent drugs as a part of the laid out regular therapy against various strong tumors, in light of the controlled delivery, better security, and viability profiles (37).These nano-formulations have undergone clinical testing for the administration of medication with adjusted PD-PK profiles, bringing about enhanced permeability and retention(EPR) -interceded particular controlled drug conveyance to the planned locus of activity with brought down portion of dose and harmfulness profiles. (40).In proven combination chemotherapies against TNBC, paclitaxel incorporated albumin nanoparticulate (Abraxane TM) and pegylated liposomal doxorubicin (Doxil TM, Lipodox TM) have replaced conventional drug solutions in clinical trials. Additionally, surface designing of the nanocarriers for dynamic focusing to overexpressed surface receptors or proteins exceptionally connected with certain tumors, as well as stimuli-sensitive (thermal/magnetic) nanocarriers, may aid in site-specific drug administration (41).These methods might be useful. To improve therapeutic outcomes with less toxicity, tailored production of nanocarriers to take advantage variables of the cancer microenvironment, including proteins, pH, assimilation processes, redox potential. Moreover, in contrast to the usage of ignorant medications. Therapeutic drug delivery using nanocarriers may aid in the inhibition of oncogenes linked to TNBC (42).

b. Conventional nanocarriers

Conventional nanocarriers are polymeric and lipidic structures with particle sizes tailored to less than 200 nm and surface qualities regulated in response to physiological conditions at the desired site. They are used for the controlled administration of hydrophilic, hydrophobic, or amphiphilic medicines. These physicochemical alterations allow therapeutic drugs targeted to tumor sites to achieve the desired PK-PD profile while also avoiding the reticuloendothelial system (RES) after systemic delivery. Using passive or active methods, such targeting of tumor cells has frequently been accomplished. The physiological characteristics of the tumor have an impact on the passive targeting of nanocarriers via diffusion-mediated cellular transport. The development of tumors has been linked to inadequate lymphatic drainage (44).Expanded tumor vessels are produced by neovascularization and matrix metalloproteinases, which also cause endothelial cells to have insufficient lymphatic drainage. Rapid cell division, elevated pro-angiogenic growth factor levels, active neovascularization, and excessive ECM deposition have all been used to classify cancerous tissues. During the neovascularization stage, hypoperfusion and insufficient oxygen and nutrition levels affect the TME and may cause metastasis (45). To work on the gamble to-help proportion of viability to poisonousness, model nanocarrier frameworks, like polymeric nanoparticles and liposomes, have generally been created. However, due to the variety of TMEs, critical clinical intra- and inter-subject variation in EPR have been seen, which results in diminished efficacy(46).The pre-clinical to clinical translational capability of the EPR-mediated detached focusing of nanocarriers is influenced by cancer stromal proportion, stromal engineering, level of perfusion, vascular design, the viability of lymphatic seepage, the level of vasogenic penetrability influencing factors (e.g., VEGF, cytokines), and vascular hindrances given by occupant fibroblasts. The combination of the aforementioned characteristics altogether affects the clinical success of EPR-mediated passive uptake, which has been hotly contested in the context of both of these malignancies. Genetic deprivation of such medication delivery and lung tissue pathophysiology prior to arriving at their planned areas of use further contribute to passive targeted nanocarriers' lack of therapeutic efficacy (47).By functionalizing or decorating the nanocarriers with explicit focusing on moieties, like peptide/aptamer functionalization, receptor ligands, Fab' fragments, monoclonal antibodies, etc. for malignant cells, it is possible to actively target them via receptor-mediated transport. This works with site-explicit conveyance of the cytotoxic specialist inside the growth microenvironment and decreases the unsavoury aftereffects and dispersion to non-target tissues. Those who are molecularly focused build up on these particular targets (cancer cells, TME) because they have a higher affinity for them. The TME has higher levels of overexpressed receptors than typical tissue, focusing on can be effectively gotten to by nanocarriers , articulation levels of overexpressed receptors ought to be connected to harmful ways of behaving (drug obstruction or forcefulness), and productive take-up/endocytosis of nanocarriers into disease cells, among other requirements. (48).

Passively designated nanocarriers in TNBC

Combination regimens based on taxanes, platins, and anthracyclines are frequently recommended as the first line of treatment for TNBC. In any case, the organization of these specialists as medication arrangements has been connected to serious poisonousness and decreased patient personal satisfaction (49). Lipid-based nanocarriers have a high stacking limit, less incidental effects, warm dependability, lower drug opposition, and more medication collection at the growth site commonly by nature. Passive tailored distribution of these powerful medicines utilizing nanocarriers has frequently proved successful in reducing toxicities. Doxorubicin's strong affinity for the cardiac phospholipid cardiolipin has been linked to particular mitochondrial accumulation, irreversible cardiomyopathy and parts of the electron transport chain are disturbed as a result(50). While reducing take-up by certain reticuloendothelial framework components, the polyethylene glycol surface coating of polymer and lipid surfaces has increased blood dissemination time. These 2nd generation nanocarriers offer excellent options for the conveyance of various remedial medications to designated locales with the control of the hydrodynamic width, surface charge, and fixed fluid layer thickness for EPR-interceded take-up and diminished toxicity(51).Doxorubicin PEGylated liposome (Doxil TM, Lipodox TM) has demonstrated regulated diminished harmfulness, drug dissemination, and practically identical viability to the drug solution (Adriamycin TM) when studied systematically in TNBC. The medication arrangement has been replaced by the nanocarrier in the laid-out drug regimens, and this has been broadly concentrated on in clinical exploration as a component of mix treatment. The non-Pegylated liposome, Myocet liposomal™ has been endorsed for use alongside cyclophosphamide or vinorelbine in metastatic bosom malignant growth structures including TNBC (43). The transporter free paclitaxel arrangement (Taxol™) containing Cremophor EL has been endorsed for use in mix treatment against TNBC. Notwithstanding, this microtubule settling specialist which represses the development of neoplastic endothelium, in the arrangement structure has been related with non-straight pharmacokinetics, serious neurotoxicity, hyperlipidaemia, and touchiness responses. Lipusu TM and covert liposomal paclitaxel have been tested in-vivo and clinically, as have lipid-based paclitaxel nano-details like EndoTAGTM-1 , LEP-ETUTM and others. When compared to the standard paclitaxel arrangement, these lipidic nanocarriers have reduced drug obstruction, secondary effects, and overall improved efficacy against both of these diseases..By substituting passively targeted nanocarriers for transporter free medication arrangements in blend chemotherapy, promising in vivo and clinical outcomes have been accomplished. Nonetheless, the need for the explicitness of the objectives connected with growth heterogeneity and medication opposition is one of the primary issues with treatment disappointments of these two forceful malignancies. The active targeting of surface-engineered nanocarriers may be used to specifically target the excessively expressed surface proteins on these cancer cells (52).

Active designated nanocarriers

The presence of various surface and hereditary biomarkers is suggested by the etiology of TNBC that are overexpressed or altered, which may be targeted for the effective delivery of treatments. For the receptor-interceded site-explicit endocytosis of the chemotherapeutic medications, ligand-formed nanocarriers coordinated against the surface overexpressed receptors on TNBC have been researched. TNBC has been characterized as a powerful form of estrogen-receptor-negative, progesterone-receptor-negative, and HER2-negative breast cancer with reduced chemotherapeutic reactivity (53). For the dynamic focusing of nanocarriers in TNBC, a few novel neoplasm-explicit receptor targets have been found, including the Disc 44, Folate receptor, EGFR, FGFR, BRCA1/2 transformation, Androgen receptor, VEGF receptor, and C-X-C chemokine receptor type 4. A poly (amidoamine)-doxorubicin dendrimer and a cell-entering peptide were coupled to EBP-1 It has a high affinity and explicitness for the EGFR receptor. This multifunctional nanocarrier demonstrated a significantly superior effect of expansion in a human bosom disease cell line (MDA-MB-231).Furthermore, BALB/c xenografts with this functionalized nanocarrier demonstrated improved anti-neoplasm effectiveness and longer survival time. On MDA-MB 231 cells, PEGylated liposomal doxorubicin covered with fibronectin-mirroring peptide PR b was used as a target for overexpressed integrin α5β1. In contrast with free medication and non-designated liposomes, the formulation greatly enhanced cellular absorption, caused tumors to regress, and reduced toxicity in animal models. It's interesting to note that patients with metastatic TNBC had a 50–86% expression rate for the folate receptor. Recently, using the desolvation approach, Hassan and colleagues created Artemether-stacked human serum albumin NPs target folate.In addition, folate-conjugated NPs showed more in-vitro cytotoxicity significantly better cellular absorption than non-targeted NPs in MDA-MB-231 breast cancer cells. Additionally, the fresh out of the plastic new PARP poly (ADP-ribose) polymerase inhibitors address a promising restorative methodology with BRCA transformations (94). NanoAssemblr Benchtop was used by Corsi and colleagues to create nano-liposomes that were nano-precipitated and then loaded with Talazoparib (100). The created nanocarriers shown to significantly boost anti-tumor effectiveness activity and cellular absorption in addition to increasing the mortality rate of mice lacking BRCA.

Similar to this, Cellular TNBC that are 80–90% CD44 positive gives an alternate targeting strategy (100). CD44 sensory receptor are comparably overexpressed in the TNBC. Because of its high fondness for CD44 sensory receptor, hyaluronic acid has been extensively studied as a polymer for CD44 targeting. To target the TNBC stem cells include the CD44 sensory receptor., Qin and colleagues have created hybrid micelles that are loaded with doxorubicin and functionalized with HA (54).The inhibition of platelet adhesion and downregulation of MMP-9, these HA-modified hybrid micelles displayed several anti-metastatic properties. In addition to these receptors, Wu and colleagues have developed brand-new dual-targeting liposomes that actively recognize both overexpressed GLUT5 and v3 targets. By specifically targeting GLUT5 and v3 with fructose and RGD peptide molecules, they functionalized liposomes. Notably, these hexose transporters transport more than 90% of the fructose, specifically GLUT5 carriers, whereas RGD peptides can be quickly distinguished by v3 integrin receptors. These double designated liposomes additionally showed further developed enemy of expansion impacts, improved enemy of cancer adequacy and higher cell take-up. Metastatic TNBC has been shown to

overexpress Forkhead Box M1 (FoxM1), a transcriptional regulator of the cell cycle that controls the cellular transitions of G1S/G2M, in addition to being a factor in the development of cancer(55).

TNBC subtype	Genetic abnormalities	Therapeutic strategies	Therapeutic targeted drugs
BL1	Cell cycle quality articulation DNA fix quality Multiplication qualities	impede cell division and the response to DNA degradation	PARP inhibitors, synthetic DNA, and cytostatic, mitosis inhibitors.
BL2	Development factor-flagging pathways gluconeogenesis, Glycolysis, Articulation of myoepithelial markers	Inhibit TP63, EGFR, and MET signalling	Cytostatic, PARP inhibitors, Growth Factor inhibitors mTOR inhibitors
IM	Invulnerable cell processes, Quality mark for medullary BC	Inhibit immune signalling	Cytostatic, PARP inhibitors, Immune checkpoint inhibitors.
M (mesenchymal)	Cell separation Cell motility EMT Development factor flagging	suppress immunological signalling Wnt, mTOR, ScrIGF1R, PI3K, TGF, Notch, and EMT inhibition	Growth Factor inhibitors, mTOR inhibitors, Scr inhibitors, PI3K inhibitors.
MSL	Like M+Low multiplication Angiogenesis qualities	Restrain Wnt, MAPK, Rac, mTOR, PI3K, Scr, TGFβ, PDGF, EMT,	Growth Factor inhibitors, mTOR inhibitors, PI3K inhibitors, MAPK inhibitors, Scr inhibitors
LAR	Atomic apocrine subtype Androgen receptor gene Luminal gene articulation design	Restrain AR flagging, FOXA1, furthermore, ERBB4 flagging	Nonsteroidal antiandrogens, mTOR inhibitors, PI3K inhibitors.

Data from (56)

TNBC Combination therapies

Because of growth variability, cancer improvement, and medication obstruction, a solitary traditional anticancer treatment or immunotherapy isn't sufficient to give an advantage. As a result, combination therapy is now considered to be the best option for treating TNBC. According to these investigations, patients with non-progressed TNBC responded well to combination therapy, while the prognosis for patients with advanced TNBC was still dismal. Among these First-line therapy for PD-L1+ patients with conventional chemotherapy in conjunction with immunotherapy had a favorable outcome (57)

Additionally, after receiving combination targeted therapy, individuals with BRCA-related transformations had a superior visualization. The novel Antibody-drug conjugates medicine Sacituzumab govite can has shown unquestionable results in second-line therapy (58), consolidated treatment of ADC is something to explore and anticipate . Without a doubt, research into tumor biological mechanisms and molecular expression characteristics is necessary for the precise, individualized treatment of TNBC. Therefore, it is advised that TNBC tumor tissues undergo routine immunomolecular expression assessment and mutation analysis, which will offer reliable justification for selecting TNBC combination therapy regimens.

Mutation in TNBC

In studies with *BRCA* genetic testing, TNBC frequency accounts for 23% BRCA2 transformation transporters and 57% BRCA1 change transporters. Both BRCA-related and basal-like breast cancers are brought on by distinct DNA fix mechanisms by homologous recombination and genomic flimsiness(59).

TREATMENT ISSUES IN TNBC

With high paces of metastasis and backslide, the forceful neoplasm physiologically displays rot in bosom cells with lymphocytic stroma. Options for chemotherapy-based TNBC treatment rely on the physiology of these diverse cancers exhibit. DNA-damaging and antimitotic medicines have a positive impact on BL1 tumors, and tyrosine kinase inhibitors and drugs that target the downstream effects of the genetic change were successful against BL2 tumors (60).SRC and PI3K inhibitors are used to treat the mesenchymal with elevated levels of EMT. Because of different cancers and the shortfall of viable oncogenetic targets along with MDR, genetic changes, and immune resistance, pathological complete response (pCR) has faced significant therapeutic challenges. Breast cancer genes BRCA1/2 and p53 (related to tumor suppression and crucial for DNA repair) abnormal expression cause taxane- and platinum-based treatments resulted in altered chemosensitivity (61). The efficiency of anthracyclines is impacted by surface CD73 protein overexpression. The anti-apoptotic MCL1 properties, the BRCA1/2, p53, retinoblastoma (RB1), PTEN, Janus kinase-2 (JAK2), PIK3, cyclin-subordinate CDK4/CDKN2A, and the proto-oncogene Myc affected by post-neo-adjuvant chemotherapy (61) and also been connected to illness relapse and unsuccessful treatments. Biomarkers used for effective targeting. BRCA signalling linked DNA fix in ordinary cell capability and this quality was noted for the transformation (protection from DNA harming chemotherapeutic and metastasis). Drugs that hinder PARP1 are used in the reduction of tumors and the reversal of treatment resistance to taxanes and anthracyclines. Additionally, TNBC's development, invasion, dissemination, and angiogenesis have all been linked to the excessive expression of several receptors, such as VEGFR and EGFR .surface proteins targeted drugs enhance PFS with no effect on OS and pCR .LAR protein restraint enhances tumor regression with reduced metastasis (62).The overexpression of the transmembrane proteins programmed cell death 1 and its ligand by tumor shows confer immune resistance, the suppression of apoptosis, T-effector-to-Treg cell conversion, and enhanced cellular death of T-effector. A small statistically significant decrease in PFS has been observed with anti-PDL1, anti-PD-1, and anti-CTLA-4 drugs (63). The upregulation of the proteins CD44/CD24, STAT3, and ALDH1 causes treatment failure for the BL1/BL2 subtype of TNBC. Tumor-associated macrophages , extracellular matrix, mesenchymal stromal cells are tumor microenvironment variables that had an impact on the TNBC MDR. The MDR has been strengthened by

cytokine production from the BCSC, including IL6/IL8 and CXCL12/CXCL7. Drug absorption in neoplasms is decreased by CAF signalling's activation of resistant cells and STAT1. The MDR taxanes and platins is enhanced by Src, a proto-oncogene, PI3K/Akt, and MSC immunomodulation. Tenascin C overexpression in the ECM improves the signal transduction that Wnt/Score blocked, strengthening the BCSC and enhancing MDR. (64). Upregulation of efflux proteins like breast cancer-resistant protein, Pgp/MDR1 cause Anthracycline and DNA-damaging drug resistance. Efflux proteins may interact, causing EMT to be induced and stabilizing BCSC that is dormant as per MDR. The immunological obstruction, stemness, calmness, and medication opposition of TNBC are improved by EMT intervened through FOXC2 . Adjusted record of ROS, cell hypoxia-inducible element, and ALDH qualities sway the tumor reprogramming neoplasms followed by MDR, metastasis, and proliferation (65). Mutations in p53 and SNAIL apoptosis-regulating genes result in a lower effectiveness failures in treating BCSC and the use of DNA-damaging medicines, which is mediated via ZEB1/CHK1. Identification and targeted BCSC protein therapy for efficacy. Clinical research occurs for better-enhanced relapse and destruction of the undifferentiated organism specialty by focusing on CSC flagging pathways, like Src tyrosine kinase, Hedgehog, Wnt and Indent,. Adjusting epigenetic targets like IGF-1R, ERK, CDK4,BMP4/BMP7, KRAS, GAS6, and TGF-2 connected with BCSC quiet, digestion, multiplication, and obstruction will increase BCSC cell death and reduce chemoresistance (66).BCSC cells and their inhibitor's ability to survive were improved by increased autophagic proteins and cellular chromosomal integrity.

RISK FACTORS

When compared to their postmenopausal and white partners, premenopausal women and women of colour had less luminal A BC (6).Genetic variation is also used for TNBC risk prediction. More youthful age, hormonal preventative use, premenopausal status, expanded equality, and high histological grade was related freely with TNBC (67).

STATISTICAL APPROACH

50%with operable TNBC undergo mastectomy (68). 906 women who have early-stage, invasive breast cancer that has increased lymph nodes and a TNBC subtype with local recurrence are being studied (69).Additionally, patients with TNBC had a higher gamble of repeat in the initial three to five years following finding than those ER-positive BC. Between 2012 and 2016, 12 percent of breast cancer diagnoses in the US were triple-negative, with a 5-year endurance rate that was 8 to 16 % poorer than that of hormone receptor-positive illness(70). SAS Software was used to analyse the dataset utilizing site-specific variables 1, 2, and 15, triple negative examples were found. Estrogen, progesterone, and HER2 receptors are identified by site-explicit elements 15, 2 and 1 respectively. The categorical classification variables include positive, negative, borderline, and other categories. For each site-explicit variable, those named negative ('020') were regarded as triple-negative. The far off stage conclusion at AJCC Stage IV, while the late stage analysis at AJCC (seventh release) Stage III and then some (71).

CONCLUSION ACKNOWLEDGEMENT

Due to its critical dissimilarity and low related endurance rates, triple-negative bosom disease is a difficult and unmanageable condition. The most recent advancements in cancer therapy nanoparticles, particularly in British Columbia (TNBC). The special qualities of source cells (leucocyte, erythrocyte, stem cells, thrombocytes, cancer cells, antibody, etc.) utilized as a transporter for remedial conveyance utilizing NDDS. These qualities include being immune system-unaffected and having a prolonged circulation time, as well as inherent biocompatibility and biodegradability, drawn out life length, bond, and homologous focusing on. Therefore, nanoparticles coated with cellular membranes produce biomimetic nanoplatforms that have excellent biocompatibility and minimal immunogenicity; it is crucial to concentrate on their upcoming translation into the clinic. Nanoelectromechanical systems currently (NEMS) are employed to track exosomes unique to the tumor and not found in healthy pluripotent cells.

ACKNOWLEDGEMENT:

(The Author would like to thank the Deanship of Scientific Research at Shaqra University for supporting this work)

REFERENCES:

1. Pseudocubic-based polymorphic phase boundary structures and their effect on the piezoelectric properties of (Li,Na,K)(NB,SB)O3-SRZRO3 lead-free ceramics - researcher: An app for Academics (2019) Researcher. Available at: https://www.researcher-app.com/paper/2043675 (Accessed: March 25, 2023).
2. Cancer.org. American Cancer Society; 2016. Available from: https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2017.html
3. Malhotra GK, Zhao X, Band H, Band V. Histological, molecular and functional subtypes of breast cancers. Cancer biology & therapy [Internet]. 2010;10(10):955–60. Available from: https://www.ncbi.nlm.nih.gov/pubmed/21057215
4. Dawson SJ, Provenzano E, Caldas C. Triple negative breast cancers: Clinical and prognostic implications. European Journal of Cancer. 2009 Sep;45:27–40.
5. Ficus spp. (fig): Ethnobotany and potential as anticancer and anti-inflammatory agents. Journal of Ethnopharmacology [Internet]. 2008 Sep 26;119(2):195–213
6. Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype. Cancer. 2007 May 1;109(9):1721–8.
7. Leary M, Heerboth S, Lapinska K, Sarkar S. Sensitization of Drug Resistant Cancer Cells: A Matter of Combination Therapy. Cancers. 2018 Dec 4;10(12):483.
8. Beltrán-Gracia E, López-Camacho A, Higuera-Ciapara I, Velázquez-Fernández JB, Vallejo-Cardona AA. Nanomedicine review: clinical developments in liposomal applications. Cancer Nanotechnology. 2019 Dec;10(1).

9. Hu Q, Sun W, Wang C, Gu Z. Recent advances of cocktail chemotherapy by combination drug delivery systems. Advanced Drug Delivery Reviews. 2016 Mar;98:19–34.
10. Marra A, Viale G, Curigliano G. Recent advances in triple negative breast cancer: the immunotherapy era. BMC Medicine. 2019 May 9;17(1).
11. Goyal A. Potential of Novel Drug Delivery Systems for Herbal Drugs. Indian Journal of Pharmaceutical Research and Education [Internet]. 2011 [cited 2023 Mar 25];45(3):225–35.
12. Kesarwani K, Gupta R. Bioavailability enhancers of herbal origin: An overview. Asian Pacific Journal of Tropical Biomedicine [Internet]. 2013 Apr;3(4):253–66.
13. Bisht S, Feldmann G, Soni S, Ravi R, Karikar C, Maitra A, et al. Polymeric nanoparticle-encapsulated curcumin ("nanocurcumin"): a novel strategy for human cancer therapy. Journal of Nanobiotechnology. 2007 Apr 17;5(1).
14. Fukuda K, Hibiya Y, Mutoh M, Koshiji M, Akao S, Fujiwara H. Inhibition of activator protein 1 activity by berberine in human hepatoma cells. Planta Medica [Internet]. 1999 May 1 [cited 2023 Mar 25];65(4):381–3
15. Chen KJ, Tang L, Garcia MA, Wang H, Lu H, Lin WY, et al. The therapeutic efficacy of camptothecin-encapsulated supramolecular nanoparticles. Biomaterials. 2012 Feb;33(4):1162–9.
16. Nisa M, Akbar S, Tariq M, Hussain Z. Effect of Cuscuta chinensis water extract on 7,12-dimethylbenz[a]anthracene-induced skin papillomas and carcinomas in mice. Journal of Ethnopharmacology [Internet]. 1986 Oct 1 [cited 2023 Mar 25];18(1):21–31.
17. Hoet PH, Brüske-Hohlfeld I, Salata OV. Nanoparticles – known and unknown health risks. Journal of Nanobiotechnology. 2004;2(1):12.
18. Medical Applications Nanotechnology Market Analysis Report [Internet]. [cited 2023 Jan 24].Available from: https://www.bccresearch.com/market research/healthcare/nanotechnology-medical-applications-market.html
19. Diaz-Arévalo D, Zeng M. Nanoparticle-based vaccines. Nanopharmaceuticals. 2020;135–50.
20. Nanotechnology Cancer Therapy and Treatment - NCI [Internet]. 2017 [cited 2023 Jan 25]. Available from: https://www.cancer.gov/nano/cancer-nanotechnology/treatment
21. Postmus PE, Kerr KM, Oudkerk M, Senan S, Waller DA, Vansteenkiste J, et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Annals of Oncology. 2017 Jul 1;28(suppl_4):iv1–21.
22. Henry NL, Hayes DF. Cancer biomarkers. Molecular Oncology [Internet]. 2012 Feb 6;6(2):140–6.
23. Easton DF, Ford D, Bishop DT. Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. American Journal of Human Genetics [Internet]. 1995 Jan 1;56(1):265–71.
24. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, et al. A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer. New England Journal of Medicine. 2004 Dec 30;351(27):2817–26.
25. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. The Lancet. 2010 Aug;376(9742):687–97.
26. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. The Lancet [Internet]. 2011 Aug;378(9793):771–84
27. Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, et al. American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer. Journal of Clinical Oncology. 2007 Nov 20;25(33):5287–312.
28. Kim Y, Jae E, Yoon M. Influence of Androgen Receptor Expression on the Survival Outcomes in Breast Cancer: A Meta-Analysis. Journal of Breast Cancer. 2015;18(2):134.
29. Wang, W., Wu, J., Zhang, P., Fei, X., Zong, Y., Chen, X., Huang, O., He, J. R., Chen, W., Li, Y., Shen, K., & Zhu, L. (2016). Prognostic and predictive value of Ki-67 in triple-negative breast cancer. Oncotarget, 7(21), 31079–31087.
30. Gumuskaya, B., Alper, M., Hucumenoglu, S., Altundag, K., Uner, A., & Guler, G. (2010). EGFR expression and gene copy number in triple-negative breast carcinoma. Cancer genetics and cytogenetics, 203(2), 222–229. https://doi.org/10.1016/j.cancergencyto.2010.07.118
31. Jansson S, Bendahl PO, Grabau DA, Falck AK, Fernö M, Aaltonen K, et al. The Three Receptor Tyrosine Kinases c-KIT, VEGFR2 and PDGFRα, Closely Spaced at 4q12, Show Increased Protein Expression in Triple-Negative Breast Cancer. Petronini PG, editor. PLoS ONE. 2014 Jul 15;9(7):e102176.
32. Niemeier LA, Dabbs DJ, Beriwal S, Striebel JM, Bhargava R. Androgen receptor in breast cancer: expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation. Modern Pathology. 2009 Nov 6;23(2):205–12.
33. Loibl S, O'Shaughnessy J, Untch M, Sikov WM, Rugo HS, McKee MD, et al. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. The Lancet Oncology [Internet]. 2018 Apr 1;19(4):497–509. Available from: https://pubmed.ncbi.nlm.nih.gov/29501363/
34. Speiser, J. J., Erşahin, C., & Osipo, C. (2013). The functional role of Notch signaling in triple-negative breast cancer. Vitamins and hormones, 93, 277–306. https://doi.org/10.1016/B978-0-12-416673-8.00013-7
35. Baselga J. Targeting the Phosphoinositide-3 (PI3) Kinase Pathway in Breast Cancer. The Oncologist [Internet]. 2011 Jan 1;16(Supplement 1):12–9. Available from: http://theoncologist.alphamedpress.org/content/16/suppl_1/12.full
36. Research C for DE and. FDA grants accelerated approval to pembrolizumab for locally recurrent unresectable or metastatic triple negative breast cancer. FDA [Internet]. 2021 Jun 11 [cited 2023 Jan 25]; Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-pembrolizumab-locally-recurrent-unresectable-or-metastatic-triple
37. Cucinotto I, Fiorillo L, Gualtieri S, Arbitrio M, Ciliberto D, Staropoli N, et al. Nanoparticle Albumin Bound Paclitaxel in the Treatment of Human Cancer: Nanodelivery Reaches Prime-Time? Journal of Drug Delivery [Internet]. 2013;2013:1–10. Available from: https://dx.doi.org/10.1155%2F2013%2F905091
38. Silva CO, Pinho JO, Lopes JM, Almeida AJ, Gaspar MM, Reis C. Current Trends in Cancer Nanotheranostics: Metallic, Polymeric, and Lipid-Based Systems. Pharmaceutics. 2019 Jan;11(1):22.
39. Gowda R, Jones NR, Banerjee S, Robertson GP. Use of Nanotechnology to Develop Multi-Drug Inhibitors For Cancer Therapy. J Nanomedicine Nanotechnol. 2013 Dec;4(6):184.
40. Mukherjee B, Maji R, Roychowdhury S, Ghosh S. Toxicological Concerns of Engineered Nanosize Drug Delivery Systems. Am J Ther. 2016 Feb;23(1):e139.
41. Biswas S, Deshpande PP, Perche F, Dodwadkar NS, Sane SD, Torchilin VP. Octa-arginine-modified pegylated liposomal doxorubicin: An effective treatment strategy for non-small cell lung cancer. Cancer Lett. 2013 Jul 10;335(1):191–200.
42. Garbuzenko OB, Kuzmov A, Taratula O, Pine SR, Minko T. Strategy to enhance lung cancer treatment by five essential elements: inhalation delivery, nanotechnology, tumor-receptor targeting, chemo- and gene therapy. Theranostics. 2019 Oct 22;9(26):8362–76.
43. García-Pinel B, Porras-Alcalá C, Ortega-Rodríguez A, Sarabia F, Prados J, Melguizo C, et al. Lipid-Based Nanoparticles: Application and Recent Advances in Cancer Treatment. Nanomaterials. 2019 Apr;9(4):638.
44. Golombek SK, May JN, Theek B, Appold L, Drude N, Kiessling F, et al. Tumor targeting via EPR: Strategies to enhance patient responses. Adv Drug Deliv Rev. 2018 May 1;130:17–38.
45. Jain RK. Normalizing Tumor Microenvironment to Treat Cancer: Bench to Bedside to Biomarkers. Journal of Clinical Oncology [Internet]. 2013 Jun 10;31(17):2205–18. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3731977/
46. Ojha T, Pathak V, Shi Y, Hennink WE, Moonen CTW, Storm G, et al. Pharmacological and physical vessel modulation strategies to improve EPR-mediated drug targeting to tumors. Adv Drug Deliv Rev. 2017 Sep 15;119:44–60.
47. Barron L, Gharib SA, Duffield JS. Lung Pericytes and Resident Fibroblasts: Busy Multitaskers. Am J Pathol. 2016 Oct 1;186(10):2519–31.
48. Pearce AK, O'Reilly RK. Insights into Active Targeting of Nanoparticles in Drug Delivery: Advances in Clinical Studies and Design Considerations for Cancer Nanomedicine. Bioconjugate Chemistry. 2019 Aug 23;30(9):2300–11.

49. Shi J, Kantoff PW, Wooster R, Farokhzad OC. Cancer nanomedicine: progress, challenges and opportunities. Nat Rev Cancer. 2017 Jan;17(1):20–37.
50. Wallace KB, Sardão VA, Oliveira PJ. Mitochondrial Determinants of Doxorubicin-Induced Cardiomyopathy. Circ Res. 2020 Mar 27;126(7):926–41.
51. Haider M, Abdin SM, Kamal L, Orive G. Nanostructured Lipid Carriers for Delivery of Chemotherapeutics: A Review. Pharmaceutics. 2020 Mar;12(3):288.
52. Ghosh S, Lalani R, Patel V, Bhowmick S, Misra A. Surface engineered liposomal delivery of therapeutics across the blood brain barrier: recent advances, challenges and opportunities. Expert Opin Drug Deliv. 2019 Dec 2;16(12):1287–311.
53. Medina MA, Oza G, Sharma A, Arriaga LG, Hernández Hernández JM, Rotello VM, et al. Triple-Negative Breast Cancer: A Review of Conventional and Advanced Therapeutic Strategies. Int J Environ Res Public Health. 2020 Jan;17(6):2078.
54. Yang Y, Long Y, Wang Y, Ren K, Li M, Zhang Z, et al. Enhanced anti-tumor and anti-metastasis therapy for triple negative breast cancer by CD44 receptor-targeted hybrid self-delivery micelles. Int J Pharm. 2020 Mar 15;577:119085.
55. O'Regan RM, Nahta R. Targeting forkhead box M1 transcription factor in breast cancer. Biochem Pharmacol. 2018 Aug 1;154:407–13.
56. Lehmann BD, Pietenpol JA. Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes. J Pathol. 2014 Jan;232(2):142–50.
57. Schmid P, Cortes J, Pusztai L, McArthur H, Kümmel S, Bergh J, et al. Pembrolizumab for Early Triple-Negative Breast Cancer. N Engl J Med. 2020 Feb 27;382(9):810–21.
58. Bardia A, Mayer IA, Diamond JR, Moroose RL, Isakoff SJ, Starodub AN, et al. Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2017 Jul 1;35(19):2141–8.
59. Gonzalez-Angulo AM, Timms KM, Liu S, Chen H, Litton JK, Potter J, et al. Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2011 Mar 1;17(5):1082–9.
60. Lehmann BD, Jovanović B, Chen X, Estrada MV, Johnson KN, Shyr Y, et al. Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection. PLOS ONE. 2016 Jun 16;11(6):e0157368.
61. Carey L, Winer E, Viale G, Cameron D, Gianni L. Triple-negative breast cancer: disease entity or title of convenience? Nat Rev Clin Oncol. 2010 Dec;7(12):683–92.
62. Astvatsaturyan K, Yue Y, Walts AE, Bose S. Androgen receptor positive triple negative breast cancer: Clinicopathologic, prognostic, and predictive features. PLOS ONE. 2018 Jun 8;13(6):e0197827.
63. Marinelli D, Mazzotta M, Pizzuti L, Krasniqi E, Gamucci T, Natoli C, et al. Neoadjuvant Immune-Checkpoint Blockade in Triple-Negative Breast Cancer: Current Evidence and Literature-Based Meta-Analysis of Randomized Trials. Cancers. 2020 Sep;12(9):2497.
64. Neophytou C, Boutsikos P, Papageorgis P. Molecular Mechanisms and Emerging Therapeutic Targets of Triple-Negative Breast Cancer Metastasis. Front Oncol. 2018;8:31.
65. Sun X, Wang M, Wang M, Yu X, Guo J, Sun T, et al. Metabolic Reprogramming in Triple-Negative Breast Cancer. Front Oncol [Internet]. 2020 [cited 2023 Jan 25];10. Available from: https://www.frontiersin.org/articles/10.3389/fonc.2020.00428
66. Nazio F, Bordi M, Cianfanelli V, Locatelli F, Cecconi F. Autophagy and cancer stem cells: molecular mechanisms and therapeutic applications. Cell Death Differ. 2019 Apr 1;26(4):690–702.
67. Lara-Medina F, Pérez-Sánchez V, Saavedra-Pérez D, Blake-Cerda M, Arce C, Motola-Kuba D, et al. Triple-negative breast cancer in Hispanic patients: high prevalence, poor prognosis, and association with menopausal status, body mass index, and parity. Cancer. 2011 Aug 15;117(16):3658–69.
68. Connor CS, Kimler BF, Mammen JMV, McGinness MK, Wagner JL, Alsop SM, et al. Impact of neoadjuvant chemotherapy on axillary nodal involvement in patients with clinically node negative triple negative breast cancer. J Surg Oncol. 2015 Feb;111(2):198–202.
69. Russo AL, Arvold ND, Niemierko A, Wong N, Wong JS, Bellon JR, et al. Margin status and the risk of local recurrence in patients with early-stage breast cancer treated with breast-conserving therapy. Breast Cancer Res Treat. 2013 Jul;140(2):353–61.
70. Howard FM, Olopade OI. Epidemiology of Triple-Negative Breast Cancer: A Review. Cancer J Sudbury Mass. 2021 Feb 1;27(1):8–16.
71. Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Annals of surgical oncology [Internet]. 2010;17(6):1471–4. Available from: https://www.ncbi.nlm.nih.gov/pubmed/20180029